Printer Friendly

Natus Medical Launches Family of Neonatal Oxygen Delivery Hoods, Heatshield, and Phototherapy Eye Protector.

Business Editors/Health/Medical Writers

SAN CARLOS, Calif.--(BUSINESS WIRE)--Oct. 1, 2003

Natus Medical Incorporated (Nasdaq: BABY) ("Natus"), today announced that the Company has started to market and distribute the family of Oxydome(TM), Oxypod(TM), Oxy-Igloo(TM), and Foldadome(TM) neonatal oxygen delivery hoods; Igloo(TM) neonatal heatshield; as well as the Biliband(TM) Eye Protector. Natus earlier announced signing an exclusive agreement with Nascor Pty. Ltd. Under the agreement, Natus will distribute the line of Nascor neonatal oxygen hoods, heatshield, and phototherapy eye protector in the United States, Canada, and Europe. Natus plans to introduce these products at the National Association of Neonatal Nurses (NANN) annual meeting scheduled for October 8 - 10 in Palm Springs, California.

Each year an estimated 300,000 babies born in the United States require some form of oxygen therapy prior to discharge from the hospital(1). One form of oxygen therapy includes the use of oxygen hoods on those babies with less severe cases of lung disease. Heatshields are intended for babies who need to be placed under radiant warmers, in incubators, or under phototherapy lights. By creating an environment of high humidity, heatshields help to control the temperature and reduce fluid loss experienced by these infants.

In contrast to other oxygen hoods and heatshields currently on the market, Natus' oxygen hoods and heatshield are aerodynamically shaped and designed to distribute an even flow of oxygen to babies and maintain a stable temperature. The hoods and heatshield are also fully transparent, allowing hospital staff and parents a clear view of infants. Additionally, they are comprised of a medical grade material that minimizes breakage associated with set-up, cleaning and storage.

All of the oxygen hoods as well as the heatshield are designed to be reusable except for the Foldadome oxygen hood. The disposable Foldadome hood is folded into a flat package, making it an ideal hood for emergency transport vehicles and other special care units with limited storage space.

The Biliband Eye Protector is designed to block harmful light from reaching the eyes of babies who undergo phototherapy treatment. Test results from an independent study demonstrate that the Biliband blocks more light than other leading brands of phototherapy eye shields(1). Moreover, unlike other phototherapy shields that may not stay in place, the Biliband's unique Y-shaped design allows it to conform to various head shapes and remain in place.

"We are pleased to be offering the Nascor products to Natus' customers, as they fit well with our existing product lines," stated Tim Johnson, president and chief executive officer of Natus. "The Bilibands are an excellent complement to our neoBLUE(TM) LED Phototherapy light. Furthermore, the neonatal oxygen hoods and heatshield allow us to expand our position in the neonatal care market."

"Due to the quality and convenience that these products bring to clinicians, we believe they will be well received," added Johnson.

About Natus

Natus Medical Incorporated develops, manufactures and markets proprietary, easy-to-use medical products that assist in the detection, treatment, monitoring and tracking of common disorders in newborns. Headquartered in San Carlos, California, the Company has operations in New York, Oregon, the United Kingdom, and Japan.

Natus' product lines include: ALGO(R) Newborn Hearing Screeners, MiniMuffs(R) Neonatal Noise Attenuators, the CO-Stat(R) End Tidal Breath Analyzer, neoBLUE(TM) LED Phototherapy device; Biliband(TM) Eye Protectors; Oxydome(TM), Oxypod(TM), Oxy-Igloo(TM), and Foldadome(TM) oxygen hoods; Igloo(TM) neonatal heatshield; Neometrics(TM) software products: MSDS(TM) Metabolic Screening Database System, CMS(TM) Case Management System, WebEBP(TM) Web Based Electronic Birth Page, VRS(TM) Voice Response System, and the Neometrics diagnostic reagent products: Accuwell(TM) TSH ELISA and Accuwell T4 EIA. Natus markets and sells its products directly in the U.S., through its wholly owned subsidiaries in the U.K. and Japan, and through distributors in 25 other countries. Additional information about Natus Medical can be found at www.natus.com.

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, particularly statements regarding the expectations, beliefs, plans, intentions, and strategies of Natus. These forward looking statements include, but are not limited to, statements regarding our strategy to bring additional products to our distribution network, our commitment to developing neonatal products that are easy to use and patient friendly, the complimentary nature of Nascor's products to our products, our opportunity to expand our market position with neonatal care customers, and expansion of distribution of Nascor's products. These statements relate to future events or Natus' future financial performance or results and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by the forward-looking statements. Forward-looking statements are only predictions and the actual events or results may differ materially. Natus cannot provide any assurance that its future results or the results implied by the forward-looking statements will meet expectations. The results could differ materially due to a number of factors, including the demand (or absence of demand) for our products and Nascor's products, continued acceptance of our products and Nascor's products, the successful development, introduction and widespread market acceptance of our products and Nascor's products, domestic and global economic conditions, competition from other companies, our inexperience in connection with the sale and distribution of Nascor products, adverse changes in our relationship with Nascor or our distribution network, integration of our efforts to sell Nascor products with our efforts to sell our existing products, the failure of third party payors to provide adequate reimbursement for the use of Natus' and Nascor's products, failure to obtain necessary regulatory clearances or approvals, adverse changes in Natus' relationships with its distributors, and product liability and intellectual property disputes or litigation. Natus disclaims any obligation to update information contained in any forward-looking statement.

For additional information and considerations regarding the risks faced by Natus, see Natus' reports on Forms 10-Q and 10-K filed and to be filed with the Securities and Exchange Commission.

natus(R); 70/40(R); ALGO(R); AABR(R); ALGO 1e(R); ALGO-1 Plus(R); ALGO 2(R); ALGO DataBook(R); Dri-Prep(R); Ear Couplers(R); Jelly Button(R); Flexicoupler(TM); Jelly Tab(TM); MiniMuffs(R); CO-Stat(R); and neoBLUE(TM); Neometrics(TM); Accuwell(TM); Accuscreen(TM); CEM(TM); CMS(TM); Neocoat(TM); MSDS(TM); VRS(TM); and WebEBP(TM) are Natus trademarks. Oxydome(TM), Oxypod(TM), Oxy-Igloo(TM), Igloo(TM), Foldadome(TM), and Biliband(TM) are trademarks of Nascor Pty Ltd.

(1) References on file at Natus
COPYRIGHT 2003 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Oct 1, 2003
Words:1090
Previous Article:Clarins Teams with Speedera to Extend Global Reach of Its Brand Through the Internet.
Next Article:S&P Global Credit Markets Digest.


Related Articles
New treatment for neonatal jaundice.
Epidural Fevers and Effects on Baby.
900 FAMILIES CELEBRATE BLESSINGS OF CHILDREN.
Odds of perinatal death are elevated when women who have had a cesarean plan to deliver vaginally. (Digests).
Natus Medical Announces First Quarter 2004 Financial Results; Revenues Increase 31% Over First Quarter 2003.
Introduction/product index.
Maternity care analysis finds danger of routine birth interventions.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters